Elsevier

Neurobiology of Aging

Volume 25, Issue 8, September 2004, Pages 1023-1032
Neurobiology of Aging

Autoimmunity in Alzheimer’s disease: increased levels of circulating IgGs binding Aβ and RAGE peptides

https://doi.org/10.1016/j.neurobiolaging.2003.11.001Get rights and content

Abstract

Plasma samples derived from 33 Alzheimer’s disease (AD) and 42 control participants were subjected to several steps to purify specific anti-(amyloid)Aβ IgGs. Affinity-purified IgGs binding the peptide Aβ1–42, a neurotoxic sequence derived from the trans-membrane amyloid precursor protein, exhibited nearly four-fold higher titers in AD patients compared with their control non-AD cohort. Affinity-purified IgGs binding a fragment of the receptor for advanced glycation end products (RAGE) likewise were increased nearly three-fold in AD individuals. and RAGE IgG titers were negatively correlated with cognitive status, i.e. the more cognitively impaired individuals tended to exhibit higher IgG titers. IgG titers were negatively correlated with age in the control group, but not with the AD group. Levels of circulating Aβ̃- and RAGE-like proteins were not different between AD and control participants, nor was there a relationship between individual IgG titers and the respective Aβ- and RAGE-like proteins. Freshly prepared leukocyte preparations were subjected to flow cytometric analysis. AD individuals exhibited significantly increased populations of cells expressing binding sites for monoclonal antibodies directed against (5.5-fold), βAPP (3.5-fold), and RAGE (2.6-fold) relative to the control group. These findings confirm the presence of circulating IgGs specifically directed at proteins implicated in immunological processes linked to AD. The close relationship between titers for Aβ and RAGE IgGs suggests the possibility that the antibodies are being produced in response to a common mechanism or protein complex (with the respective epitopes) linked to the disease.

Introduction

Alzheimer’s disease (AD) is a progressive neurodegenerative disease affecting nerve cells located within higher cortical centers that ultimately results in impaired cognition, including a gradual decline in memory, judgment, and communication. Neuropathological and genetic data strongly support a primary role for amyloid peptides, particularly amyloid β protein (Aβ), which accumulate as senile plaques in brain parenchyma, in the pathogenesis of AD. Mutations which are located either immediately adjacent to the Aβ cleavage product sequence 1–42 (N or C terminus), or within the Aβ sequence, have been shown to alter the enzymatic processing of amyloid precursor protein in ways that result in increased production of Aβ1–42 or Aβ1–43 (highly self-aggregating and neurotoxic peptides). Simultaneously, the levels of α-secretase-derived amyloid peptides (less self-aggregating), are decreased, with both factors causally linked to certain inherited (and rarer) forms of AD (for review, see [31]).

In the more prevalent late-onset forms of AD, the roles of specific mutations are less obvious, although some risk factors such as the dose of the ApoE4 allele are known. Age is still the most reliable and potent risk factor for late-onset AD. Therefore it is likely that age-dependent processes play an important part in the appearance of specific AD pathology. Monnier et al. [21] proposed that advanced glycation end product (AGE)-mediated cross-linking of long-lived proteins contribute to the age-related decline in the function of cells and tissues with normal aging. Under oxidative conditions, intermediates of glycation can give rise to ε-carboxymethyl lysine, a major glycoxidation product [9]. In addition to glucose, many sugars, sugar phosphates, ascorbic acid, glycoxal and methyl glycoxal have been shown to generate glycation products at a higher rate than glucose. High levels of gene expression coding the receptor for AGEs (RAGE) occur in AD brain within hippocampal pyramidal cells, cortical neurons, glial cells, and white matter [6]. Some evidence exists to suggest that RAGE permits the accumulation, and supports the aggregation of Aβ, resulting in inflammation and cytotoxicity in neuronal cells [15], [37]. RAGE also may represent a key protein involved in mediating the toxic effects of Aβ on microglial cells, possibly by triggering the inflammatory processes and cellular dysfunction that are prominent in AD pathology [20], [37].

These findings have engendered new research into the roles of AGEs and RAGEs in AD pathology [2], [29], [36]. For example, Aβ peptides have been demonstrated to serve as binding ligands for RAGE, inducing a cascade of events leading to the generation of reactive oxygen species in microglial cells [15], [17], [37]. RAGE has been co-localized nearby neuritic plaque deposits, in the cells of Aβ-containing blood vessels, and in endothelial, neuronal and microglial cells in AD brain tissue at concentrations much greater than those of age-matched control-derived tissues [27]. Therefore, humanized monoclonal antibodies specific to RAGE and/or to Aβ peptides could be valuable not only as diagnostic probes, but as potential therapeutic modalities [29].

Previously we immunized mice with an AGE originally derived from purified human brain neurofilament protein [23]. Unexpectedly, the animals generated IgGs against a peptide fragment of the receptor for RAGE, and against human amyloid Aβ peptide, suggesting that the AGE-immunogen bound endogenous circulating RAGE- and Aβ-like peptides, possibly forming complexes with increased immunogenicity. The presence of circulating Aβ-like antibodies in the peripheral blood of AD patients has been previously reported [7], [14], [24], although the titers of these antibodies have not always been correlated specifically with the disease. We report here that by first purifying specific anti-Aβ IgGs from individual samples derived from AD individuals, relatively high levels were expressed relative to controls. Perhaps even more intriguing, as with our earlier studies in the mouse, AD individuals also expressed high levels of anti-RAGE IgGs.

Section snippets

Participants and evaluation

A total of 75 particpants, 33 Alzheimer’s disease (AD) and 42 healthy seniors (controls), were recruited from patients seen at specialized clinics for assessment and management of memory disorders at the Augusta Georgia Veterans Affairs Medical Center (VAMC), Georgia State University, and the Medical College of Georgia Neurological Disease Database Repository (NDDR), a core program of the Alzheimer’s Research Center. Control participants (healthy seniors) were recruited from unaffected blood

Results

Table 1 lists the distribution of various demographic and clinical variables for the AD participants and healthy seniors (controls). There were no statistically significant differences in the distributions of sex, race, family history of AD, or diabetes between AD and control individuals. The distribution of the tertile groups for RAGE and Aβ were different between AD and control individuals with AD individuals tending to be in the higher tertiles than the control individuals for both the RAGE

Discussion

There is evidence that the immune system plays a protective role in AD. Microglial cells can degrade Aβ peptides, and recent studies suggest that auto-reactive Aβ presenting T cells may be relevant to the peripheral elimination of the peptide [34]. In the early stages of AD the immune system appears to play a supportive role in the elimination of amyloid peptides. During the course of disease progression, failure to eliminate toxic Aβ peptides along with activation of the innate immune system

Acknowledgements

This work was supported by the Office of Research and Development, Medical Research Service, Department of Veterans Affairs, and by the Medical College of Georgia Combined Intramural Grant Program. The authors would like to thank Dr. David M. Stern, Dean, School of Medicine and Dr. Jeffery L. Rausch, Professor of Psychiatry and Health Behavior at the Medical College of Georgia for their helpful comments and insights regarding this work.

References (37)

  • A.M. Schmidt et al.

    The biology of the receptor for advanced glycation end products and its ligands

    Biochim. Biophys. Acta

    (2000)
  • D.M. Stern et al.

    Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes

    Ageing Res. Rev.

    (2002)
  • A. Tamaoka et al.

    Amyloid beta protein in plasma from patients with sporadic Alzheimer’s disease

    J. Neurological Sci.

    (1996)
  • K. Trieb et al.

    APP peptides stiumulate lymphocyte proliferation in normals, but not in patients with Alzheimer’s disease

    Neurobiol. Aging

    (1996)
  • M. Brownlee et al.

    Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications

    N. Engl. J. Med.

    (1988)
  • L.G. Bucciarelli et al.

    RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease

    Cell. Mol. Life Sci.

    (2002)
  • D. Galasko

    Biological markers and the treatment of Alzheimer’s disease

    J. Mol. Neurosci.

    (2001)
  • L.B. Hassing et al.

    Diabetes mellitus is a risk factor for vascular dementia, but not for Alzheimer’s disease: a population-based study of the oldest old

    Int. Psychogeriatr.

    (2002)
  • Cited by (108)

    • Elevated IgM against Nε-(Carboxyethyl)lysine-modified Apolipoprotein A1 peptide 141–147 in Taiwanese with Alzheimer's disease

      2018, Clinical Biochemistry
      Citation Excerpt :

      In addition, AD is associated with autoimmunity. High levels of RAGE autoantibodies were detected in AD as well as in diabetes [13]. The titers of RAGE autoantibodies especially IgGs were negatively correlated with cognitive status with the highest autoantibody level in the AD-diabetic group, followed by the non-diabetic AD group, the elderly diabetic group and the control elderly group.

    • Biomarker for Alzheimer's Disease

      2018, Precision Medicine: Tools and Quantitative Approaches
    View all citing articles on Scopus
    View full text